EORTC-20981-LYMG

Intergroup Collaborative Study (EORTC 20981) "Rituximab (Mabthera*) in remission induction and maintenance treatment of relapsed / resistant follicular non-Hodgkin's lymphoma : a phase III randomized clinical trial" lymphoma : a phase III randomised clinical trial - Intergroup Collaborative Study (EORTC 20981) Including Amenmdment 4 (28.6.2000)
Study documentation
Trial StatusFurther follow-up after final analysis of primary endpoint
DatesDate of activation: 21-May-99
Date Step1 close: 26-Apr-04
Date Step2 close: 09-Dec-05
Data management at EORTCFull
Phase3
Randomized trial
Type-
Targeted Sample size752
Number of steps2
DrugCyclophosphamide
Doxorubicin
Prednisone
Rituximab
Vincristine
Study StaffAnton Hagenbeek
Study Coordinator - Academisch Medisch Centrum - Universiteit van Amsterdam, Amsterdam
M.h.j. Van Oers
Study Coordinator - Academisch Medisch Centrum - Universiteit van Amsterdam, Amsterdam
Livia Giurgea
Data Manager - EORTC Headquarters, Brussels
livia.giurgea (at) eortc.be - +32 27741692
Sarah Nuyens
Project Manager - EORTC Headquarters, Brussels
sarah.nuyens (at) eortc.be - +32 27741089
Type of cancerNon Hodgkins Lymphoma
Participating GroupsEORTC Lymphoma Group(Coordinating Group)
Australasian Leukaemia and Lymphoma Group
British National Lymphoma Group
Hemato-Oncologie Volwassenen Nederland
NCIC Clinical Trial Group
Nordic Lymphoma Group
Schweizerisches Arbeitsgemeinschaft Klin. Krebsforschung
South African Non-Hodgkin Lymphoma Clinical Trials Group
Protocol summaryClinicalTrials.gov
NCT numberNCT00004179
EudraCT